University of Texas Southwestern Medical Center clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
20 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 9 with minor changes only.
- Notable: IMPACT-MACS · Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Phase changed: Not applicable → Phase 4
- Minor: Obesity in the Aged Trial completed
- Notable: Non-Invasive Testing to Evaluate Wound Healing in Diabetes Suspended trial terminated
- Notable: Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Primary completion pushed from Aug 30, 2026 to May 30, 2027
- Minor: TEST · Transference of Established Simulated Skills (TEST) Trial Trial completed
- Notable: Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk · Type 2 Diabetes Primary completion pushed from Sep 15, 2026 to May 15, 2027
- Minor: Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure Primary completion pushed from Aug 1, 2028 to Sep 1, 2028
- Notable: RESOLVE-CKD · REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial Primary and study completion dates pushed to May 1, 2029
- Minor: VITAS · Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Enrollment closed, study ongoing
- Notable: Cerebellar Transcranial Direct Current Stimulation (tDCS) · Autism Spectrum Disorder: Raynor Cerebellum Project Primary and study completion pushed from Jun 30, 2026 to Dec 30, 2027
- Minor: SF · Targeting Social Function in Anxiety and Eating Disorders Enrollment closed, study ongoing
- Minor: Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia Trial completed
- Notable: HIV/HBV/HCV Triple Screening in Primary Care Primary and study completion pushed from Jun 2027 to Dec 31, 2027
- Notable: Diuretic Tuner Clinical Decision Support Primary and study completion pushed from Aug 2026 to Aug 2028
- Minor: TRI-MR · Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Trial status changed: Enrolling by Invitation → Active, Not Recruiting
- Minor: KMD · Ketamine for Methamphetamine Use Disorder Trial completed
- Notable: T-STEM · Tirzepatide for Methamphetamine Use Disorder Recruitment opened
- Stopped: Pre-operative Tumor Treating Fields · Resectable Lung Cancer Withdrawn before enrolling
- Notable: Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) Primary completion pushed from Sep 1, 2026 to Sep 1, 2027
- Minor: Skin Wetting in Burn Survivors Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-12 | NCT07930299 Neuromodulation of Executive Control for Substance Use Disorders | Not Yet Recruiting | |
| 2026-11-12 | NCT07934329 CCS Transitions to Adult Care | Not Yet Recruiting | |
| 2026-10-21 | NCT07886853 Pragmatic Interventions to Advance Cancer Survivor Outcomes | Not Yet Recruiting | |
| 2026-10-21 | NCT07887737 Deep Brain Stimulation Guided by Brain Mapping to Treat Cognitive Impairment | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 10 | |
| Phase 1 | 14 | |
| Phase 1/2 | 12 | |
| Phase 2 | 33 | |
| Phase 2/3 | 2 | |
| Phase 3 | 6 | |
| Phase 4 | 11 |
Not charted: 150 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 50
Heart Disease (19) · Depression (14) · Heart Failure (11) · Breast Cancer (9) · Liver Cancer (9) · Obesity (9) · Prostate Cancer (9) · Lung Cancer (8) · Chronic Kidney Disease (7) · Diabetes (7)
Get alerts when University of Texas Southwestern Medical Center's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.